Relay Therapeutics, Inc. Stock Price, News & Analysis

Relay Therapeutics (RLAY), a clinical-stage precision medicine company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Dr. Sanjiv Patel, will deliver a presentation on Tuesday, January 14, 2025, at 7:30 a.m. PT.

The presentation will be accessible through a live webcast on the company's website under the Events section in News & Events. Interested parties can access the webcast through the IR portal at ir.relaytx.com. An archived version of the presentation will remain available for 30 days after the event.

Relay Therapeutics specializes in transforming drug discovery by combining advanced computational and experimental technologies.

Relay Therapeutics (RLAY) announced updated interim data for RLY-2608, showing an 11.4-month median progression-free survival in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at the recommended Phase 2 dose. The study demonstrated a 39% confirmed objective response rate across all patients and 67% in patients with kinase mutations.

The drug showed a favorable tolerability profile, with 94% median dose intensity and mostly low-grade treatment-related adverse events. Among 64 patients at the recommended dose, only 31% experienced Grade 3 adverse events, with no Grade 4-5 events reported.

The company plans to initiate a pivotal Phase 2 study in 2025 and reported approximately $840 million in cash and investments as of Q3 2024.

Relay Therapeutics (RLAY) announced it will present updated clinical data for RLY-2608 in combination with fulvestrant for treating PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer at the San Antonio Breast Cancer Symposium (December 10-13, 2024). The presentation, titled 'Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial', will be part of a poster spotlight session on targeting ER and PI3K pathway. The company will host a conference call on December 11, 2024, at 7:00 a.m. ET to discuss the findings.

Relay Therapeutics (RLAY) and Elevar Therapeutics have announced an exclusive global licensing agreement for lirafugratinib, a potential best-in-class FGFR2 inhibitor for treating FGFR2-driven cholangiocarcinoma and other solid tumors. Under the agreement, Elevar receives worldwide development and commercialization rights, while Relay can earn up to $500 million in payments, including $75 million in upfront and regulatory milestones, plus up to double-digit royalties on global sales. The FDA has granted lirafugratinib breakthrough therapy and orphan drug designations, and recommended filing an NDA for FGFR2-driven CCA first, followed by a supplemental NDA for other solid tumors.

Relay Therapeutics (Nasdaq: RLAY) has announced its participation in four upcoming investor conferences in November and December 2024. The company will participate in fireside chats at the Guggenheim Healthcare Innovation Conference (Nov 13), Stifel Healthcare Conference (Nov 18), Jefferies London Healthcare Conference (Nov 20), and Citizens JMP Hematology and Oncology Summit (Dec 2). All sessions will be webcast live and accessible through Relay's website, with recordings available for 30 days after each event.

Relay Therapeutics reported its third quarter 2024 financial results and corporate highlights. Key highlights include interim data for RLY-2608 + fulvestrant showing a 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The company plans to initiate a pivotal trial in 2025.

Relay Therapeutics has $840 million in cash, expected to fund operations into the second half of 2027. Revenue for Q3 2024 was $0, down from $25.2 million in Q3 2023. R&D expenses decreased to $76.6 million, while G&A expenses increased to $19.8 million. The net loss was $88.1 million, or $0.63 per share.

Corporate highlights include a $230 million follow-on offering and a $50 million annual savings from streamlining the research organization. Looking ahead, the company plans several clinical trial initiations and expansions in 2024 and 2025.

Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company, announced it will report its third quarter 2024 financial results and corporate highlights on November 6, 2024 after the U.S. financial markets close.

Relay Therapeutics (Nasdaq: RLAY) has announced the pricing of a public offering of 28,571,429 shares of its common stock at $7.00 per share. The company expects to raise approximately $200 million in gross proceeds, before deducting underwriting discounts and expenses. Underwriters have a 30-day option to purchase up to an additional 4,285,714 shares. The offering is expected to close around September 12, 2024, subject to customary conditions. Goldman Sachs & Co. , TD Cowen, Stifel, and BofA Securities are acting as joint book-running managers, with Raymond James as co-manager.

Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company, has announced a proposed public offering of $200 million of common stock shares. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares. Goldman Sachs & Co. , TD Cowen, Stifel, and BofA Securities are acting as joint book-running managers, with Raymond James as co-manager. The offering is subject to market conditions, and its completion is not guaranteed. Shares will be offered through an effective shelf registration statement previously filed with the SEC. A preliminary prospectus supplement and accompanying prospectus will be filed and made available to potential investors.